Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ARS Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for ARS Pharmaceuticals, Inc.

SPRY

ARS Pharmaceuticals, Inc.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing neffy, a needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions, including anaphylaxis. With a significant market opportunity of approximately $3 billion in the U.S., ARS targets 20 million patients at risk of severe allergies. The company is innovating with direct-to-consumer marketing and expanding regulatory approvals globally, aiming to transform epinephrine delivery.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ARS Pharmaceuticals, Inc.

1
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports 184% Revenue Growth to $22.7 Million, Despite Increased Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $171.3 Million Net Loss Amid Neffy Commercial Launch

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $32.5 Million Revenue in Q3 2025, Driven by Neffy Sales

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $15.7M Revenue and $44.9M Net Loss for Quarter Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $7.973 Million Revenue in Q1 2025, Net Loss Increases to $33.940 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $8M Net Income for 2024, Driven by Neffy Launch

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports Revenue Growth, Net Loss in Q3 2024 Amid Product Launch and Expansion Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments